Related Experiment Video
Updated: Jan 11, 2026
06:30
Intraductal Delivery to the Rabbit Mammary Gland
Published on: March 9, 2017
9.7K
Current Management of Intraductal Papillary Mucinous Neoplasms.
Tommaso Pollini1, Paul Wong1, Ajay V Maker1
1Division of Surgical Oncology, Department of Surgery, University of California San Francisco, San Francisco, CA, USA.
Hematology/Oncology Clinics of North America
|November 12, 2025
Summary
Intraductal papillary mucinous neoplasms (IPMNs) are common pancreatic tumors. Management depends on subtype, with branch-duct IPMNs often surveilled and main-duct IPMNs resected, alongside discussions on advanced diagnostic and surveillance strategies.
Area of Science:
- Gastroenterology and Hepatology
- Surgical Oncology
- Pancreatic Pathology
Background:
- Intraductal papillary mucinous neoplasms (IPMNs) are increasingly diagnosed pancreatic cystic lesions.
- Prevalence of IPMNs rises with age, necessitating clear management guidelines.
- IPMNs are classified into main-duct (MD) and branch-duct (BD) variants based on pancreatic duct involvement, dictating distinct clinical pathways.
Purpose of the Study:
- To review current management strategies for pancreatic IPMNs.
- To differentiate therapeutic approaches for MD-IPMNs versus BD-IPMNs.
- To discuss the role of advanced techniques in IPMN diagnosis and surveillance.
Main Methods:
- Review of existing literature and clinical guidelines for IPMN management.
- Analysis of factors influencing treatment decisions, including IPMN subtype and risk stratification.
- Discussion of emerging technologies such as molecular profiling and intraoperative pancreatoscopy.
Main Results:
- Branch-duct IPMNs (BD-IPMNs) are typically low-risk and managed with surveillance.
- Main-duct IPMNs (MD-IPMNs) generally require surgical resection.
- Standard pancreatic resection with lymphadenectomy is the recommended surgical approach when indicated.
Conclusions:
- Management of IPMNs is subtype-dependent, with a clear distinction between BD-IPMN and MD-IPMN treatment.
- Molecular profiling and intraoperative pancreatoscopy offer potential advancements in IPMN assessment.
- Optimizing surveillance end points is crucial for effective long-term management of IPMNs.
